Overview

Effect of Acetazolamide on Postural Control in Patients With Respiratory Disease at Altitude

Status:
Completed
Trial end date:
2018-08-02
Target enrollment:
0
Participant gender:
All
Summary
In this trial, the investigators will evaluate the effect of acetazolamide (375 mg per day) vs. placebo on postural control at acute altitude exposure in patients with COPD.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University of Zurich
Collaborator:
National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov
Treatments:
Acetazolamide
Criteria
Inclusion Criteria:

- Male and female patients, age 18-75 yrs.

- COPD diagnosed according to GOLD, FEV1 40-80% predicted, SpO2 ≥92% at 750 m.

- Born, raised and currently living at low altitude (<800m).

- Written informed consent.

Exclusion Criteria:

- COPD exacerbation, very severe COPD with hypoxemia at low altitude (FEV1/FVC <0.7,
FEV1 <40% predicted, oxygen saturation on room air <92% at 750 m).

- Comorbidities such as uncontrolled cardiovascular disease, i.e., unstable systemic
arterial hypertension, coronary artery disease; previous stroke; OSA; pneumothorax in
the last 2 months.

- Internal, neurologic, rheumatologic or psychiatric disease including current heavy
smoking (>20 cigarettes per day)

- Known renal failure or allergy to acetazolamide and other sulfonamides